Clinical Trials
95 trialsStudy of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Lumos Pharma
KEYMAKER-U02
Merck Sharp & Dohme LLC
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Phase Ib of L-NMMA and Pembrolizumab
The Methodist Hospital Research Institute
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
UNC Lineberger Comprehensive Cancer Center
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Seagen Inc.
MK-4700-001
Merck Sharp & Dohme LLC
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Emory University
MAK
Institute of Oncology Ljubljana
LEAP-003
Merck Sharp & Dohme LLC
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
LEAP-003
Merck Sharp & Dohme LLC
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
SPOTLIGHT203
Highlight Therapeutics
ATLAS-IT-05
Lytix Biopharma AS
KEYMAKER-U02
Merck Sharp & Dohme LLC
KEYMAKER-U02
Merck Sharp & Dohme LLC
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Eisai Inc.
KEYVIBE-010
Merck Sharp & Dohme LLC
Keynote-593
Merck Sharp & Dohme LLC
KEYMAKER-U02
Merck Sharp & Dohme LLC
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
Incyte Corporation
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
MacroGenics
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Yale University
MK3475-C01
Sheba Medical Center
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
Mayo Clinic
Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
Regeneron Pharmaceuticals
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Mural Oncology, Inc
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Thomas Jefferson University
A Study of SEA-CD40 Given With Other Drugs in Cancers
Seagen Inc.
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
Syndax Pharmaceuticals
Meteor 1
GlaxoSmithKline
KEYNOTE-555
Merck Sharp & Dohme LLC
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
Haukeland University Hospital
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
Amgen
Dendritic Cell Vaccination in Patients With Advanced Melanoma
University of Pennsylvania
IVY
Eli Lilly and Company
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
Imaging FDG Flare in Melanoma
Abramson Cancer Center at Penn Medicine
Fecal Microbiota Transplant (FMT) in Melanoma Patients
University of Pittsburgh
A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma
Hoffmann-La Roche
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
University of Colorado, Denver
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
Keynote-151
Merck Sharp & Dohme LLC